Literature DB >> 6319741

An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200).

M Hummel, D Thorley-Lawson, E Kieff.   

Abstract

The genes encoding the two major Epstein-Barr virus glycoproteins (gp350/300 and gp220/200) have been mapped to a 5-kilobase fragment of the viral genome (BamHI-L). This fragment encodes 3.4- and 2.8-kilobase RNAs which translate proteins of 135 and 100 kilodaltons, respectively. Both proteins react with antiserum specific for gp350/300 and gp220/200. The 135-kilodalton protein is identical in size to the nascent polypeptide precursor to gp350/300, and the 100-kilodalton protein is the expected size of the polypeptide precursor to gp220/200.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6319741      PMCID： PMC255481     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  Epstein-Barr virus-induced proteins. II. Analysis of surface polypeptides from EBV-producing and -superinfected cells by immunoprecipitation.

Authors:  N Meuller-Lantzsch; B Georg; N Yamamoto; H zur Hausen
Journal:  Virology       Date:  1980-04-30       Impact factor: 3.616

2.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells.

Authors:  M Heller; T Dambaugh; E Kieff
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

4.  Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

5.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

Authors:  G R Pearson; B Vroman; B Chase; T Sculley; M Hummel; E Kieff
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

7.  Radioimmune precipitation study comparing the Epstein-Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA).

Authors:  L F Qualtiere; G R Pearson
Journal:  Virology       Date:  1980-04-30       Impact factor: 3.616

8.  Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping.

Authors:  T Dambaugh; C Beisel; M Hummel; W King; S Fennewald; A Cheung; M Heller; N Raab-Traub; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

9.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  Polypeptides of the Epstein-Barr virus membrane antigen complex.

Authors:  D A Thorley-Lawson; C M Edson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103
View more
  23 in total

Review 1.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

Review 2.  Epstein-Barr virus entry.

Authors:  Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

3.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment.

Authors:  M Mackett; M J Conway; J R Arrand; R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein.

Authors:  M S Cho; G Milman; S D Hayward
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

9.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.